US FDA Fulfills Annual Antibiotic Guidance Goal With Three Women’s Health Guidances
Executive Summary
Final guidance documents for bacterial vaginosis, vulvovaginal candidiasis, and uncomplicated urinary tract infections contain few changes from draft.
You may also be interested in...
Antibiotics With Bacteria-Specific, Rather Than Site-Specific, Indication Headed To US FDA
Entasis is seeking a pathogen-specific approval for its antibiotic/beta lactamase inhibitor candidate rather than an indication specific the site of an infection. Achaogen’s earlier failure to do the same may have helped set a path.
Accelerated Approvals: Conversions Still Outweigh Withdrawals, But Takeda’s Exkivity Brings 2023’s Pull Count To Six
US FDA’s Oncologic Drugs Advisory Committee will convene in November for a ‘general discussion about delayed confirmatory trials’ and the ‘continued optimization of the accelerated approval process.’
US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer
Fourteen user fee goal dates are on the October calendar, including three novel agents, according to the Pink Sheet US FDA Performance Tracker.